Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: Week 16 results from the randomized multicenter CareRA trial

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Verschueren, Patrick ^a,b   De Cock, Diederik ^a   Corluy, Luk ^c,d   Joos, Rik ^e   Langenaken, Christine ^c,d   Taelman, Veerle ^f   Raeman, Frank ^e   Ravelingien, Isabelle ^g   Vandevyvere, Klaas ^h   Lenaerts, Jan ^c,d   Geens, Elke ^e   Geusens, Piet ^i,j   Vanhoof, Johan ⁱ   Durnez, Anne ^h   Remans, Jan ^k   Vander Cruyssen, Bert ^g   Van Essche, Els ^l   Sileghem, An ^m   De Brabanter, Griet ⁿ   Joly, Johan ^b   Van der Elst, Kristien ^a,b   Meyfroidt, Sabrina ^a   Westhovens, Rene ^a,b   Maeyaert, Bea ^a   Devinck, Mieke ^a   Verbruggen, Ann ^a   de Vlam, Kurt ^a   Volders, Pascal ^a   Van Den Bosch, Filip ^a   more..

^a SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Reuma Instituut   (Belgium)

^d Jessa Ziekenhuis   (Belgium)

^e Algemeen Ziekenhuis Jan Palfijn   (Belgium)

^f Heilig Hart Ziekenhuis   (Belgium)

^g OLV HOSPITAL   (Belgium)

^h AZ GROENINGE   (Belgium)

ⁱ ReumaClinic Genk and UHasselt   (Belgium)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Reuma instituut Genk   (Belgium)

^l IMELDA HOSPITAL   (Belgium)

^m ReumaClinic Genk   (Belgium)

ⁿ AZ St Lucas   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI CITRULLINATED PROTEIN ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ADULT; AGITATION; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEARTBURN; HUMAN; INCREASED APPETITE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMATITIS; TENDINITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADULT; AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOMARKERS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928822071     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0611-8     Document Type: Article

References (27)

1. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625-39.
3. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M, Guideline Development Group. Management of rheumatoid arthritis: summary of NICE guidance. BMJ. 2009;338:b702.
4. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309-18. A published erratum appears in. Lancet. 1998;351:220.
5. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999;353:1568-73.
6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146:406-15.
7. De Cock D, Vanderschueren G, Meyfroidt S, Joly J, Westhovens R, Verschueren P. Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. Clin Rheumatol. 2014;33:125-30.
8. De Cock D, Vanderschueren G, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, et al. The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. Semin Arthritis Rheum. 2014;43:627-31.
9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.
10. Sakellariou G, Scirè CA, Zambon A, Caporali R, Montecucco C. Performance of the 2010 classification criteria for rheumatoid arthritis: a systematic literature review and a meta-analysis. PLoS One. 2013;8, e56528.
11. Wevers-de Boer KV, Heimans L, Huizinga TW, Allaart CF. Drug therapy in undifferentiated arthritis: a systematic literature review. Ann Rheum Dis. 2013;72:1436-44.
12. Porter D, Dale J, Sattar N. How low to aim in rheumatoid arthritis? Learning from other disciplines. Ann Rheum Dis. 2014;73:480-2.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
14. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Annals Rheum Dis. 2015;74:27-34.
15. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9.
16. Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol. 2009;38:166-72.
17. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009;60:1242-9.
18. Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-22.
19. Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F. Glucocorticoids. Best Pract Res Clin Rheumatol. 2011;25:891-900.
20. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50:3408-17.
21. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156:329-39.
22. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1010-4.
23. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72:1905-13.
24. Meyfroidt S, van Hulst L, De Cock D, Van der Elst K, Joly J, Westhovens R, et al. Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. Scand J Rheumatol. 2014;43:265-72.
25. Meyfroidt S, Van der Elst K, De Cock D, Joly J, Westhovens R, Hulscher M, et al. Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis. Patient Educ Couns. 2015;98:384-90.
26. Ajeganova S, Huizinga TWJ. Seronegative and seropositive RA: alike but different? Nat Rev Rheumatol. 2015;11:8-9.
27. Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014;41:2361-9.